Tracking visuospatial difficulties over time in people with parietal lobe glioma
Official title: Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma
Run by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT07286929 · Data updated 2026-11-12
This project will test whether visuospatial problems in adults with parietal lobe glioma get better, worse, or stay the same before and after surgical removal of the tumor.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | December 3, 2024 |
| Main results expected | October 2026 |
| Study ends | October 2026 |
| Registry record updated | December 16, 2025 |
| Trial ID | NCT07286929 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 who speak Italian, have a suspected parietal lobe glioma, and are planned for surgical resection without prior chemotherapy or radiotherapy and without other major CNS or neurodegenerative disease.
✕Probably not a fit
Patients with tumors outside the parietal lobe, those unable to undergo resection, those with prior chemo/radiation, or with other major CNS or neurodegenerative conditions are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, prospective observational study will enroll 40 adults with low- or high-grade parietal lobe glioma who are candidates for surgical resection. Participants will complete a battery of visuospatial neuropsychological tests (Line Bisection, Bell and Letter Cancellation, Apple Cancellation, Reading test, Fluff test) at pre-surgery screening and at approximately 3–4 months and 6 months after surgery. Test performance will be compared to normative cut-offs and correlated with patient-reported ADL/IADL measures, MRI radiology, and histological/molecular tumor data. The study aims to define the prevalence and temporal pattern of visuospatial deficits to guide personalized treatment and rehabilitation pathways.
Why it matters
Potential benefit: If successful, results could help tailor post-surgical rehabilitation and surgical planning to better preserve daily functioning in patients with parietal lobe glioma.
How similar studies have gone: Similar neuropsychological methods have been used to characterize visuospatial deficits after stroke and brain injury with useful results, but longitudinal data specifically in parietal lobe glioma patients are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \>18 years old * Patients must understand the Italian Language * Patients with suspected parietal lobe glioma Exclusion Criteria: * Tumor site other than parietal lobe. * Patients who cannot undergo surgical resection (stereotactic/open biopsy). * Patients who received a previous chemotherapy and/or radiotherapy treatment. * Patients with a history of intracranial mass lesion or traumatic brain injury. * Patients with a history of other CNS diseases (e.g., stroke, metastasis). * Patients with diagnosis of neurodegenerative disease (i.e. Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis).
Where it's running
-
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy Recruiting
Study contacts
- Principal investigator: Francesco Di Meco, MD — Fondazione IRCCS Istituto Neurologico Carlo Besta
- Study coordinator: Francesco Di Meco, MD
- Email: francesco.dimeco@istituto-besta.it
- Phone: + 39 02.2394
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.